Jump to content
Pharmacy CJC-1295 An after-hours editorial digest of the CJC-1295 literature — what the GHRH-analog studies actually measured, why it is paired with ipamorelin, and where the DAC-vs-no-DAC story really stands.

purpose, ownership, and limits

About this CJC-1295 research guide

The pages explain published studies. The name includes 'pharmacy,' but no pharmacy service is offered.

No owner is named, and the site sells nothing

The subject here is CJC-1295, a lab-made drug that prompts growth-hormone release. This page tells you what the guide does and what it cannot do.

The site does not name a person or company as its owner. It says no clinic or care team runs these pages.

The site doesn't make, stock, prescribe, or sell CJC-1295. The pages explain CJC-1295 studies and keep each figure next to its source.

The main questions cover timing, the drug pair, and a stopped Phase 2 study, an early test for benefit. None of those study facts gives you personal care.

The word pharmacy does not promise a service

The site's name contains the word "pharmacy." No drug counter, clinic, or person writing prescriptions stands behind that name.

Nothing here is mixed, handed out, or sold. There is no pharmacist, care team, or stock of products.

No health agency has cleared CJC-1295 for people [9]. The site explains research and cannot help anyone get the drug.

The sources separate findings from unanswered claims

Two small Phase 1 studies, early checks of how a drug acts, found longer rises in growth hormone [2]. They also tracked IGF-1, a blood protein that rises after growth hormone, and estimated a 5.8-8.1 day half-life.

Other studies explain why pairing the drug with ipamorelin can raise more hormone [7]. No fair human study proves fat loss, a best dose, or long-term safety [9].

Public listings disagree about the exact lab formula and weight for things called CJC-1295. That dispute may reflect the two forms; it cannot tell you that a product is safe or that its contents are certain.